pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Cell Therapy · news · pharmadog
← back to Cell Therapy
News · Cell Therapy
218
stories
5h
Significant stock movers of September: Viking soars, Longeveron slides
biospace
17h
Trio of scientists who developed neuron light switches win Nobel Prize in Physiology or Medicine
fiercebiotech
19h
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
19h
Weighing the risks of CAR T in autoimmune disease as Kyverna nears market
biospace
20h
Swiss CDMOs and CROs ride a new wave of growth amid surge in global demand
biospace
3d
Foghorn cuts 40% of workforce
biospace
4d
Chutes & Ladders—Bayer taps new chief medical officer; Cantor appointed PhRMA CEO
fiercebiotech
5d
Atara, Pierre Fabre resubmit twice-rebuffed cell therapy after FDA flips again
biospace
5d
PhRMA names next CEO; Pierre Fabre takes third swing at Ebvallo approval
biopharma dive
5d
BioNTech to close German manufacturing plants after failing to find buyers
biospace
5d
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
biospace
6d
Spark co-founder Steven Altschuler is back with an immune-resetting biotech
endpoints
7d
Adicet Bio shares promising look at CAR-T for lupus, but stock drops anyway
endpoints
7d
ai3Bio emerging from stealth to ‘take the gun out of the hands of the immune system’
fiercebiotech
7d
An ‘off-the-shelf’ CAR-T therapy from Adicet shows promise against lupus
biopharma dive
7d
STAT+: It really is bleak out there, and list prices matter
stat
7d
STAT+: AbbVie wins FDA nod for Parkinson’s pill
stat
7d
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
7d
Regenerative medicine needs more than stem cells
biospace
10d
STAT+: Lilly wins approval for once-weekly insulin shot
stat
10d
Endpoints 11 2026 winner Azalea melds gene editing and CAR-T
endpoints
10d
Adicet Bio CAR-T sparks lupus remissions in early trial as ‘new era’ of autoimmune treatment approaches
fiercebiotech
11d
STAT+: FDA commissioner nominee Heidi Overton keeps opinions to herself in Senate hearing
stat
11d
The FDA’s Overton era, and dispatches from Shanghai
stat
11d
US senators grill FDA nominee Overton on ability to ‘stand up’ to Trump
biospace
11d
STAT+: Kyverna’s cell therapy shows lasting autoimmune benefit
stat
11d
Kyverna steps closer to FDA-first CAR T for an autoimmune condition with durability data
biospace
12d
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
14d
Mikhail, Davis on board with regulatory framework tailored to rare disease therapies
biospace
17d
Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug
biopharma dive
← prev
page 1 of 8
next →
